Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Rhea-AI Summary

Aytu BioPharma, Inc. CEO, Josh Disbrow, will participate in a fireside chat and one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference on February 1, 2024. The webcasted fireside chat will be accessible on the company's website and can be replayed after the event. Management will also engage in virtual one-on-one meetings throughout the conference.

DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.

Company Webcast
The webcasted fireside chat will take place at 11:45am ET on Thursday, February 1, 2024. The webcast can be accessed at https://wsw.com/webcast/lytham10/aytu/2125040 or on the Company's website at https://investors.aytubio.com/. The webcast will also be available for replay following the event.

1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/select2024invreg/.

Further information on the conference is available at https://lythampartners.com/select2024.

About Aytu BioPharma, Inc.
Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.

Contacts for Investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
moki@aytubio.com

Robert Blum or Roger Weiss
Lytham Partners
AYTU@lythampartners.com

SOURCE: Aytu BioPharma, Inc.

View the original press release on accesswire.com

FAQ

When will the webcasted fireside chat take place?

The webcasted fireside chat will take place at 11:45am ET on Thursday, February 1, 2024.

Where can the webcast be accessed?

The webcast can be accessed at https://wsw.com/webcast/lytham10/aytu/2125040 or on the Company's website at https://investors.aytubio.com/.

How can investors arrange one-on-one meetings with management?

Investors can arrange one-on-one meetings with management by contacting Lytham Partners at 1x1@lythampartners.com or registering for the event at https://lythampartners.com/select2024invreg/.

Where can further information on the conference be found?

Further information on the conference is available at https://lythampartners.com/select2024.